Treatment for primary postpartum haemorrhage

Area of Science:

• Obstetrics and Gynecology
• Maternal Health
• Evidence-Based Medicine

Background:

• Primary postpartum hemorrhage (PPH) is a leading cause of maternal mortality globally.
• Effective interventions are crucial for managing PPH and improving maternal outcomes.

Purpose of the Study:

• To evaluate the effectiveness and safety of interventions for treating primary PPH.
• To compare different treatment strategies for PPH.

Main Methods:

• Systematic review of randomized controlled trials (RCTs).
• Searched Cochrane Pregnancy and Childbirth Group's Trials Register.
• Included 10 RCTs with 4052 participants.

Main Results:

• Adjunctive misoprostol (600-1000 mcg) with uterotonics showed no benefit for mortality, morbidity, or hysterectomy.
• Sublingual misoprostol (800 mcg) vs. oxytocin infusion for PPH: similar outcomes but more blood loss (>1000 mL) with misoprostol.
• Misoprostol associated with increased vomiting and shivering; tranexamic acid and compression studies were too small.

Conclusions:

• Oxytocin infusion is more effective and safer than misoprostol as first-line PPH therapy.
• Adjunctive misoprostol provides no added benefit when oxytocin is used for PPH.
• Further research needed for tranexamic acid, compression methods, and refractory PPH treatments.